New test aims to spot kidney cancer early with just a blood or urine sample
NCT ID NCT02664883
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study is testing a new blood and urine test to see if it can find kidney cancer early and track how well treatment is working. Researchers will compare test results from healthy people, patients with early-stage kidney cancer, and patients with advanced kidney cancer. The goal is to develop a simple, non-invasive way to detect and monitor the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
37 people
The number who actually took part.
- Started
-
Sep 2015
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with renal cell carcinoma and their accompanying partners who are seen at the Urologic Oncology and Medical Oncology Clinics of the Keck Medical Center of University Southern California (USC), Norris Cancer Center, and USC-Los Angeles County Hospital will be recruited for this trial.
- Ages
-
25 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects enrolled in this study must meet one of the 3 following criteria: * Group 1: Healthy individual with no history of cancer or hematuria * Group 2: Subject with a diagnosis of localized renal cell carcinoma (by imaging and eventual pathology) scheduled to undergo nephrectomy * Group 3: Subject with a diagnosis of metastatic renal cell cancer(by imaging and eventual pathology) who is scheduled to begin a new systemic therapy * Any type of renal cell carcinoma (RCC); any prior therapy * Performance status: 0-3 * Leukocytes \>= 3,000/mcL (frequently used - numbers listed are examples, investigator should modify as needed) * Absolute neutrophil count \>= 1,500/mcL (frequently used - numbers listed are examples, investigator should modify as needed) * Ability to understand and the willingness to sign a written informed consent Exclusion Criteria: * For normal subject arm: no evidence of cancer or hematuria * For localized RCC arm: no evidence of metastatic disease, second cancer, prior chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier * For metastatic RCC arm: no evidence of second cancer, prior chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier * For all subjects: uncontrolled intercurrent illness including, but not limited to previous or current history of second malignancy unrelated to renal cell carcinoma; autoimmune disease or immune deficiency, chronic treatment with immunomodulatory therapies (e.g. glucocorticoids); significant trauma, surgery, or infection in the past two weeks or psychiatric illness/social situations that would limit compliance with study requirements
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy subject are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Pre-Surgery Tune-Up: could it help older adults recover faster?
- Lifestyle makeover: can diet and exercise curb cancer risk?
- Radioactive antibody hunt: could a new scan outsmart hidden kidney cancer?
- Can a special MRI spot kidney cancer better?
- Brain mapping study probes how we sense and move
- Can MRI and tissue tests predict breast cancer before it starts?